Savara Inc. (NASDAQ:SVRA) Receives $10.14 Average Target Price from Brokerages

Shares of Savara Inc. (NASDAQ:SVRA) have been given an average recommendation of “Moderate Buy” by the eight research firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $10.1429.

Several equities analysts have weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a report on Friday, July 17th. Wall Street Zen lowered Savara from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th.

Hedge Funds Weigh In On Savara

Several large investors have recently modified their holdings of SVRA. BlackRock Inc. bought a new stake in Savara during the 2nd quarter valued at $76,966,000. Polar Capital Holdings Plc purchased a new position in Savara during the fourth quarter valued at approximately $50,086,000. Nantahala Capital Management LLC purchased a new position in Savara during the second quarter valued at approximately $42,977,150. RTW Investments LP bought a new stake in Savara during the 4th quarter worth approximately $35,893,000. Finally, VR Adviser LLC increased its holdings in Savara by 172.7% during the 2nd quarter. VR Adviser LLC now owns 8,884,263 shares of the company’s stock worth $20,256,000 after acquiring an additional 5,626,624 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Price Performance

SVRA opened at $5.26 on Monday. The company has a quick ratio of 10.13, a current ratio of 10.13 and a debt-to-equity ratio of 0.21. The stock has a market cap of $1.08 billion, a price-to-earnings ratio of -9.07 and a beta of 0.29. Savara has a twelve month low of $3.19 and a twelve month high of $7.01. The company’s 50-day moving average price is $5.70 and its two-hundred day moving average price is $5.48.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). As a group, equities analysts expect that Savara will post -0.62 earnings per share for the current year.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.